Combination chemotherapy for advanced gastric cancer
Author Information
Author(s): Lee S-H, Kang W K, Park J, Kim H Y, Kim J H, Lee S I, Park J O, Kim K, Jung C W, Park Y S, Im Y-H, Lee M H, Park K
Primary Institution: Samsung Medical Center, Sungkyunkwan University School of Medicine
Hypothesis
Can combination chemotherapy with epirubicin, docetaxel, and cisplatin improve outcomes in patients with metastatic or recurrent, unresectable gastric cancer?
Conclusion
The combination chemotherapy with EDP is active and relatively well tolerated in patients with metastatic or recurrent, unresectable gastric cancer.
Supporting Evidence
- The response rate was 47%, indicating the treatment was effective.
- The median overall survival was 11.0 months, which is a favorable outcome.
- Patients experienced manageable side effects, with no treatment-related mortality.
Takeaway
Doctors tested a new combination of three cancer drugs to help people with a tough type of stomach cancer, and it worked pretty well for many patients.
Methodology
This was an open-label, single institution, phase II study of combination therapy with EDP in metastatic or recurrent, unresectable gastric cancer.
Potential Biases
Selection bias may have influenced the results due to the nature of phase II trials.
Limitations
The study was limited to a single institution and had a small sample size.
Participant Demographics
The median age of participants was 52 years, with 25 men and 5 women.
Statistical Information
P-Value
0.039
Confidence Interval
95% CI, 28–66%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website